Drug intelligence / Profile preview

JBPOS041C

Development stage: Preclinical
Lead developer: Bio-Pharm Solutions
Modality: Small Molecules
Administration: Oral

Overview

JBPOS041C is a small molecule therapeutic candidate developed by Bio-Pharm Solutions for the treatment of epilepsy, pain management, and glioma. It functions as an antagonist of the metabotropic glutamate receptor 1 (mGluR1), a target involved in the regulation of excitatory neurotransmission within the central nervous system. By modulating mGluR1 activity, JBPOS041C aims to mitigate neuronal hyperexcitability associated with seizure disorders and chronic pain, while also potentially addressing glutamate-driven tumor progression in gliomas. The drug is currently in the preclinical stage of development, following the company's lead candidate, JBPOS0101.

Targets

GRM1 (Metabotropic glutamate receptor 1)

Beyond the preview

Go deeper on JBPOS041C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JBPOS041C.

Explore the full profile